An interventional study of Active treatment and Placebo in Osteoarthritis (OA), Osteoarthritis (OA) of the Hip and Osteoarthritis (OA) of the Knee, sponsored by Middlesex University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Middlesex University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Osteoarthritis with a site in United Kingdom — 14 open to participants now, 38 under way, 1 of them phase 3. Osteoarthritis · United Kingdom.
Among the 167 studies in Osteoarthritis with a site in United Kingdom, this one is the 95th largest by planned enrollment of the 114 interventional ones that give a count, is one of 4 that started in 2025, is one of 59 with no phase, reaches primary completion later than 6 of the 37 other live ones, and was the 165th registered.
2,974 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.
Browse Osteoarthritis studies →14 of the 167 studies in Osteoarthritis with a site in United Kingdom are open now. Recruiting first, the newest first:
Golden Jubilee National Hospital · Sites in United Kingdom
Ages 18+
Eli Lilly and Company · Sites in United Kingdom, United States, Argentina and 10 more countries
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+
Scarcell Therapeutics S.A.S. · Sites in United Kingdom
Ages 40+
Bournemouth University · Sites in United Kingdom
Ages 45+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 19 · Phase 4 16
First in 1997; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 2,239 interventional studies indexed under Osteoarthritis.
Median enrollment 108 across the 114 interventional studies, 150 across the 53 observational. Of the 110 that completed or were terminated, 28 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 167 have an industry lead sponsor. The 10 most frequent:
Middlesex University is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Middlesex University has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
10 of the studies in Osteoarthritis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550024CrannMedSakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT05889598Loughborough UniversityResistance Exercise Training to Improve Bone and Articular Cartilage Health in Women | 2026-12-31 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 167 studies in Osteoarthritis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness and safety of a combined herbal supplement containing Boswellia serrata, Curcuma longa, and Vitis vinifera in adults with clinically diagnosed knee or hip osteoarthritis.
The primary objective is to determine whether the supplement improves osteoarthritis-related symptoms.
The supplement will be compared with a placebo.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary supplement containing standardised herbal extracts of Boswellia Serrata (525 mg), Curcuma Longa (150 mg), Vitis vinifera (75 mg)
Dietary Supplement: Active treatment
Dietary supplement placebo containing no standardised herbal extracts or other active ingredients.
Other: Placebo
A dietary supplement containing standardised herbal extracts of Boswellia serrata (525 mg), Curcuma longa (150 mg), Vitis vinifera (75 mg). Four times a day.
A placebo containing no standardised herbal extracts or other active ingredients. Four times a day.
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) score
Western Ontario and McMaster Universities Arthritis Index, a validated, specialised instrument used to assess pain, stiffness, and physical function in people with osteoarthritis. Scores range from 0 to 96 (Likert version), with higher scores indicating worse pain (0-20), stiffness (0-8), and physical function (0-68).
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in Numeric Rating Scale (NRS) score
Numeric Rating Scale. A specialised pain assessment tool, where patients rate their pain intensity on a scale from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain; higher scores indicate worse outcomes.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in Intermittent and Constant Osteoarthritis Pain knee/hip (ICOAP) score
ICOAP. A Measure of Intermittent and Constant Osteoarthritis Pain knee/hip To assess two distinct types of pain experienced by people with osteoarthritis-intermittent pain (comes and goes, 0 - 24) and constant pain (persistent, ongoing pain, 0 - 20). Scores range from 0 to 44, with higher scores indicating more severe osteoarthritis related pain.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) score
EuroQol 5-Dimension 5-Level questionnaire. A generic, widely used tool to measure health-related quality of life. It measures five dimensions: Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression. A score of 1 indicates no problems, while 5 indicates extreme problems in the respective dimension. In addition, the EQ Visual Analogue Scale (EQ-VAS) records the respondent's self-rated health on a vertical scale ranging from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in urinary C-terminal telopeptide of type II collagen (uCTX-II) levels
uCTX-II (urinary C-terminal telopeptide of type II collagen) is a biochemical marker measured in urine that reflects type II collagen degradation, which occurs primarily in articular cartilage.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) score.
Western Ontario and McMaster Universities Arthritis Index, a validated, specialised instrument used to assess pain, stiffness, and physical function in people with osteoarthritis. Scores range from 0 to 96 (Likert version), with higher scores indicating worse pain (0-20), stiffness (0-8), and physical function (0-68).
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in Numeric Rating Scale (NRS) score
Numeric Rating Scale. A specialised pain assessment tool, where patients rate their pain intensity on a scale from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain; higher scores indicate worse outcomes.
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in Intermittent and Constant Osteoarthritis Pain knee/hip (ICOAP) score
ICOAP. A Measure of Intermittent and Constant Osteoarthritis Pain knee/hip To assess two distinct types of pain experienced by people with osteoarthritis-intermittent pain (comes and goes, 0 - 24) and constant pain (persistent, ongoing pain, 0 - 20). Scores range from 0 to 44, with higher scores indicating more severe osteoarthritis related pain.
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in Lequesne Functional Index (LFI) score
Lequesne Functional Index. A specialised questionnaire used to evaluate the severity of osteoarthritis and its impact on daily function, particularly for the hip and knee. Scores range from 0 to 24, with higher scores indicating greater severity and worse functional impairment.
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in Lequesne Functional Index (LFI) score
Lequesne Functional Index. A specialised questionnaire used to evaluate the severity of osteoarthritis and its impact on daily function, particularly for the hip and knee. Scores range from 0 to 24, with higher scores indicating greater severity and worse functional impairment.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Evaluation of Minimal Clinically Important Difference for measured scores
Minimal Clinically Important Difference assessed by Patient Global Impression of Change. PGIC is a specialised patient-reported outcome tool.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in 30-Second Chair Stand Test
30-Second Chair Stand Test is a functional assessment that measures lower-body strength and endurance by recording the number of times an individual can rise to a full standing position from a seated position in 30 seconds, without using their arms.
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in 30-Second Chair Stand Test
30-Second Chair Stand Test is a functional assessment that measures lower-body strength and endurance by recording the number of times an individual can rise to a full standing position from a seated position in 30 seconds, without using their arms.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in Stair Climb Test
Stair Climb Test is a functional performance assessment that measures lower-limb strength, power, and mobility by timing how quickly an individual ascends and descends a set of stairs.
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in Stair Climb Test
Stair Climb Test is a functional performance assessment that measures lower-limb strength, power, and mobility by timing how quickly an individual ascends and descends a set of stairs.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Change in 40-metre Fast-Paced Walk Test
The 40-metre Fast-Paced Walk Test (4 × 10 m) is a functional mobility assessment that measures walking speed and dynamic balance by timing how quickly an individual completes four 10-metre walks at a fast but safe pace.
Time frame: Change from baseline to the end of Week 1 of supplementation
Change in the 40-metre Fast-Paced Walk Test (4 × 10 m)
The 40-metre Fast-Paced Walk Test (4 × 10 m) is a functional mobility assessment that measures walking speed and dynamic balance by timing how quickly an individual completes four 10-metre walks at a fast but safe pace.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Global Physical Activity Questionnaire
The GPAQ will be used to monitor physical activity patterns in participants, and detect possible changes.
Time frame: Change from the start of the intervention to Week 4 of supplementation
Adverse events
Collection of adverse events to assess the safety and tolerability of the supplement
Time frame: The length of intervention: 4 weeks
Rescue medication
The use of rescue medication
Time frame: The length of intervention: 4 weeks
Satisfaction with remotely controlled study
Participants will be asked to complete a remote study satisfaction survey
Time frame: At the end of the study: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Sep 2026, 9 months after the start.
Of 576 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 9 months is below that.
Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Middlesex University